Materialise NV (MTLS) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Materialise (MTLS) by buying shares or fractional shares at any major US broker, through an ETF that holds it, or as one holding in a focused 3d printing basket. Materialise is a Belgian additive manufacturing company that combines 3D printing software, a large printing service bureau, and a medical device business making patient-specific surgical guides and implants. As of October 16, 2026 the US-listed shares closed around $8.06, up about 48% year to date, for a market cap near $464 million. Figures on this page are approximate; verify current numbers before deciding. Walnut is not an investment adviser.

MTLS stock price

As of 2026-11-16, Materialise NV (MTLS) last closed at $6.21, up 4.5% over the past year. Over the past 52 weeks it has traded between $4.80 and $8.75.

MTLS last close
$6.21
1 day
-4.31%
1 month
-22.37%
1 year
+4.55%
52-week range
$4.80 to $8.75
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Materialise NV's investor relations page. Walnut is informational, not investment advice.

MTLS key stats

At $6.21 on November 16, 2026, Materialise NV (MTLS) has a market cap of $355M and a P/E of 23.9 on trailing earnings (24.0 on forward earnings).

Market cap
$355M
P/E (trailing)
23.9
P/E (forward)
24.0
EPS (trailing 12 months)
$0.26
Price to book
1.3
Beta
1.30

Market cap, P/E and yield are measured at the $6.21 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Materialise NV (MTLS)?

The last two weeks for Materialise NV, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MTLS closed at $6.21 on November 16, 2026, down 9.7% over the past five trading days (from $6.88).
  • On November 16, 2026, Materialise NV filed a current report (6-K) with the SEC. Read the 6-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Materialise NV (MTLS) do?

Materialise is a Belgian additive manufacturing company that combines 3D printing software, a large printing service bureau, and a medical device business making patient-specific surgical guides and implants. It reports in euros through three segments (Medical, Manufacturing and Software) and has about 2,556 employees.

Materialise is more diversified than a pure printer maker, with software and medical revenue alongside the service bureau, and the segments have very different economics. In the second quarter of 2026 group revenue was about EUR 70.1 million, up more than 8% year over year, with adjusted EBITDA of about EUR 9.6 million (a 13.7% margin) and net profit of about EUR 3.3 million, or EUR 0.06 per share, ahead of the roughly 0.04 consensus. Medical grew more than 12% (medical devices up 19%), Manufacturing grew nearly 7% to about EUR 23.6 million on a 40% jump in aerospace work, and Software fell 3% to about EUR 9.6 million. Management reaffirmed 2026 revenue guidance of EUR 273 to 283 million and raised adjusted EBIT guidance to EUR 12 to 14 million.

The company sold its RapidFit business in April and its Eyewear business in July 2026 (keeping a 20% stake in Eyewear), held about EUR 74 million of net cash at mid-year, and has been buying back ADSs. Over the trailing twelve months revenue was about $273 million and net income about $13 million. The shares have risen about 48% year to date and 32% over one year as of October 16, 2026, and third-quarter results are due October 28, 2026.

What's driving Materialise NV (MTLS)?

Medical is the differentiated business

Materialise makes patient-specific surgical guides and implants from CT scans, a regulated business with clinical validation and hospital relationships behind it. That is harder to replicate than printing capacity and carries better economics than general service work. Medical devices revenue grew 19% in the second quarter of 2026, and the company also took a stake in Replasia, a Belgian medtech startup focused on hip preservation.

Software licensed across the industry

Its build-preparation and workflow software is used with third-party printers, including competitors' machines. That gives Materialise a position independent of whose hardware wins. About 86% of software revenue is recurring, though segment revenue fell 3% in Q2 2026 and the CO-AM Pro platform launch is the near-term product to watch.

Service bureau scale, tilting toward aerospace and defense

Operating one of the larger printing bureaus means Materialise sells parts rather than machines, which tracks production demand rather than customer capital budgets. In 2026 aerospace has been the fastest-growing piece (up 40% in Q2), helped by a partnership with Lufthansa Technik, and Materialise is also working on a defense project for the Belgian Cyber Force. The segment was still slightly loss-making at the adjusted EBITDA level in Q2, but the loss narrowed.

Portfolio clean-up and a net-cash balance sheet

Divesting RapidFit and most of Eyewear narrows the company to its core segments. With about EUR 74 million of net cash at mid-2026, positive free cash flow (about EUR 11.4 million in the first half) and an ongoing ADS buyback, Materialise has room to invest without relying on outside funding.

What are the risks to Materialise NV (MTLS)?

The general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. Medical revenue is regulated, so approvals and reimbursement decisions affect it directly. As a Belgian company reporting in euros, results are exposed to currency movements against the dollar. The additive industry overall has grown more slowly than forecast for a decade. Operating margins are thin (under 1% on a trailing GAAP basis), so small revenue misses swing earnings, and after a 48% year-to-date rise the shares trade near the analyst mean target of about $8.82 with only three analysts covering the stock. Leadership turnover in the medical segment (its head left in September 2026) is a further execution watch point.

What is the Materialise NV (MTLS) forecast?

3 analysts publish price targets on MTLS, averaging $9.95 as of November 2026, or +60.2% against the $6.21 share price on November 16, 2026. The published targets run from $8.03 to $13.01, a moderate spread, and the ratings split 2 buy, 1 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MTLS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is MTLS a buy or a sell?

We give no verdict on Materialise NV. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Medical is the differentiated business. Materialise makes patient-specific surgical guides and implants from CT scans, a regulated business with clinical validation and hospital relationships behind it. The most optimistic published target, $13.01, assumes this works close to its best case.

The case against. The general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. The most pessimistic target, $8.03, is roughly what MTLS is worth if this bites instead.

Read the full bull and bear case on MTLS, including what would have to change to break either one. Walnut is not an investment adviser.

Has Materialise NV (MTLS) split its stock?

No. Materialise NV (MTLS) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Materialise NV (MTLS) valued?

Market cap, P/E and dividend yield at today's price are in the MTLS key stats above. The business figures below come from Materialise NV's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$273 million
  • Revenue growth (Q2 2026, YoY): ~+8%
  • Net income (TTM): ~$13 million
  • Gross margin: ~57%
  • 2026 revenue guidance: EUR 273-283 million
  • Dividend: None

As of October 2026: Materialise trades at about 1.7x trailing sales and roughly 29x trailing earnings, with about $134 million of cash against about $60 million of debt. The multiple has expanded with the share price in 2026, while consensus expects only modest earnings per share this year and next, so the valuation leans on medical and aerospace growth continuing. Reported figures are converted from euros and move with the exchange rate.

What themes does Materialise NV (MTLS) fit?

These are the investment theses MTLS naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with Materialise NV (MTLS)?

Printing services

Protolabs and Xometry compete directly for on-demand manufacturing work, both with substantial digital quoting platforms. Numerous regional service bureaus compete on price for commodity printing.

Medical additive

Stryker, Zimmer Biomet and other orthopaedic majors produce their own patient-specific instrumentation, and are customers and competitors at different times.

Additive software

Printer makers such as Stratasys and 3D Systems bundle their own build-preparation software, and industrial software groups (Autodesk, Siemens, Dassault Systemes) offer design-to-print tools, so Materialise's cross-platform software competes with both.

What stocks are similar to Materialise NV (MTLS)?

Other names that sit close to MTLS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Materialise NV (MTLS)

There are three common ways to get MTLS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MTLS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MTLS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Materialise NV (MTLS)

Materialise (MTLS) is best understood through the 3d printing theme it belongs to. Materialise is more diversified than a pure printer maker, with software and medical revenue alongside the service bureau, and in 2026 the medical devices business and aerospace printing have done the growing while software revenue has slipped. It is a small, profitable, net-cash company whose share price has rerated sharply this year.

More on Materialise NV (MTLS)

Whether MTLS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MTLS a buy or a sell?, and where the stock could go from here in the MTLS stock forecast.

For income investors, whether MTLS pays a dividend and how the payout looks is covered in does MTLS pay a dividend? And to weigh MTLS against a peer, read the full side-by-side comparisons: MTLS vs DDD and MTLS vs SSYS.

Wondering how MTLS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Materialise NV

Ask Walnut's AI anything about MTLS and see how it fits what you own.

FAQ

What does Materialise do?

+

Materialise is a Belgian additive manufacturing company that combines 3D printing software, a large printing service bureau, and a medical device business making patient-specific surgical guides and implants. It reports through Medical, Manufacturing and Software segments.

Is MTLS a good stock to buy?

+

That depends on your thesis, time horizon and what you already hold, not on any single call. The case and the risks are both set out on this page. Walnut is informational and not a registered investment adviser, so treat this as research rather than a recommendation.

How did Materialise do in its latest quarter?

+

In Q2 2026 revenue rose more than 8% to about EUR 70.1 million, adjusted EBITDA rose almost 16% to about EUR 9.6 million, and net profit was about EUR 3.3 million (EUR 0.06 per share, ahead of estimates). Medical devices grew 19% and aerospace 40%, while software fell 3%. Management raised 2026 adjusted EBIT guidance to EUR 12 to 14 million. Q3 results are due October 28, 2026.

How has MTLS stock performed in 2026?

+

As of the October 16, 2026 close of about $8.06, MTLS was up roughly 48% year to date and about 32% over one year, near the top of its 52-week range of about $4.78 to $8.82. Past performance does not predict future returns.

Who competes with Materialise?

+

Printing services: Protolabs and Xometry compete directly for on-demand manufacturing work, both with substantial digital quoting platforms. Numerous regional service bureaus compete on price for commodity printing. Medical additive: Stryker, Zimmer Biomet and other orthopaedic majors produce their own patient-specific instrumentation, and are customers and competitors at different times.

What are the main risks of MTLS?

+

The general service-bureau business is competitive and price-sensitive, and printing capacity is not scarce. Medical revenue is regulated, so approvals and reimbursement decisions affect it directly. As a Belgian company reporting in euros, results are exposed to currency movements against the dollar. Margins are thin, and the additive industry overall has grown more slowly than forecast for a decade.

Does MTLS pay a dividend?

+

No. Materialise does not pay a dividend as of October 2026. It returns some cash through ADS buybacks instead, spending about EUR 5.2 million on close to 1.1 million ADSs in the first half of 2026.

How do I buy MTLS shares?

+

Open an account at any major US broker, search for MTLS, and place a buy order. Most brokers support fractional shares, so you can invest a fixed dollar amount rather than buying whole shares. Walnut connects to the broker you already use rather than holding your money itself.

What theme does MTLS belong to?

+

Materialise sits in the 3d printing theme, which groups the companies exposed to the same underlying thesis so you can see them together and compare how the group has performed against the S&P 500.

Is MTLS a large company?

+

No. With a market cap of about $464 million as of October 2026 and trailing revenue near $273 million, Materialise is a small-cap stock. Company size affects liquidity and volatility, so it is worth knowing before sizing a position.

Guides that feature MTLS

MTLS is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Materialise NV's investor relations page or your broker before making investment decisions.